Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 12 of 23

  1. varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule completed

    1 trial

  2. widow spider antivenom

    BRIGHT MINDS BIOSCIENCES INC.

    Arachnidism

    phase 2 mab completed

    1 trial

  3. xue-fu-zhu-yu capsule

    BRIGHT MINDS BIOSCIENCES INC.

    Qi Stagnation and Blood Stasis Syndrome

    phase 2 small molecule completed

    1 trial

  4. zonisamide

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  5. 1 Nalmefene implant

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Abuse and Addiction

    phase 1 small molecule active

    1 trial

  6. 10-223-00277-01

    BRIGHT MINDS BIOSCIENCES INC.

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  7. 11C-OMAR

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 1 small molecule completed

    1 trial

  8. 124I-labeled monoclonal antibody Mu 11-1F4

    BRIGHT MINDS BIOSCIENCES INC.

    AL Amyloidosis

    phase 1 mab completed

    1 trial

  9. 15-Valent Pneumococcal Conjugate Vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    Pneumonia, Pneumococcal

    phase 1 mab active

    1 trial

  10. 15403/23-24

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus, Type 2

    phase 1 small molecule active

    1 trial

  11. 2-4 of the drugs listed below

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 1 small molecule completed

    1 trial

  12. 2-4 of the drugs listed below

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Dependence

    phase 1 small molecule completed

    1 trial

  13. 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Abuse

    phase 1 small molecule terminated

    1 trial

  14. 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 1 small molecule terminated

    1 trial

  15. 400 mg Cannabidiol

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Pain

    phase 1 small molecule active

    1 trial

  16. AAV8-hCocH

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence, in Remission

    phase 1 small molecule active

    1 trial

  17. AFQ056

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule terminated

    1 trial

  18. ALKS 33-BUP

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 1 small molecule completed

    1 trial

  19. APR002

    BRIGHT MINDS BIOSCIENCES INC.

    COVID-19

    phase 1 small molecule completed

    1 trial

  20. ARISE with AR

    BRIGHT MINDS BIOSCIENCES INC.

    Pediatric Cancer

    phase 1 other active

    1 trial

  21. ART-I02

    BRIGHT MINDS BIOSCIENCES INC.

    Arthritis, Rheumatoid

    phase 1 gene therapy active

    1 trial

  22. ASP8062

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule completed

    1 trial

  23. ASP8082

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule completed

    1 trial

  24. ATAFENOVIR 200 MG KAPSUL

    BRIGHT MINDS BIOSCIENCES INC.

    Bioequivalence

    phase 1 small molecule active

    1 trial

  25. ATI-1013 (0.2 g)

    BRIGHT MINDS BIOSCIENCES INC.

    Thromboangiitis Obliterans (Buerger's Disease)

    phase 1 mab active

    1 trial

  26. AV-101

    BRIGHT MINDS BIOSCIENCES INC.

    Neuropathic Pain

    phase 1 small molecule completed

    1 trial

  27. AVICOD 200 MG Film Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Bioequivalence

    phase 1 small molecule active

    1 trial

  28. Active Cannabis

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule active

    1 trial

  29. Active Delta-9-THC

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 1 small molecule completed

    1 trial

  30. Adolescent Methamphetamine Treament (AMT)

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior and Mental Disorders

    phase 1 other completed

    1 trial

  31. Alcohol

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Drinking

    phase 1 small molecule completed

    1 trial

  32. Alcohol

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 1 small molecule completed

    1 trial

  33. Alcohol + Caffeine Beverage

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol or Other Drugs Effects

    phase 1 small molecule completed

    1 trial

  34. Aripiprazole

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule completed

    1 trial

  35. Arm 1: IL13Ra2-specific CAR Tcm cells

    BRIGHT MINDS BIOSCIENCES INC.

    Recurrent Glioblastoma

    phase 1 mab active

    1 trial

  36. Automated Contingency Management (ACM) software

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate-Replacement Therapy

    phase 1 other completed

    1 trial

  37. BC-101

    BRIGHT MINDS BIOSCIENCES INC.

    Nasolabial Fold Wrinkles

    phase 1 mab active

    1 trial

  38. BF-Amlodipine Tablet 10mg

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  39. BF-Gliclazide Tablet 80mg

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  40. BF-Lisinopril Tablets 20mg

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule active

    1 trial

  41. BF-Methyldopa 250mg Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  42. BF-Metoprolol Tablet 100mg

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule active

    1 trial

  43. BICX104

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 1 small molecule completed

    1 trial

  44. BICX104 naltrexone implantable pellet

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Adult Male and Female Volunteers

    phase 1 small molecule active

    1 trial

  45. BIOPIN-6 Active Implant with Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 other completed

    1 trial

  46. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  47. BPT567

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial

  48. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    phase 1 other completed

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.